

**Final Draft Agenda**  
**34<sup>th</sup> meeting of the Committee for Socio-economic Analysis**

**13 – 17 March 2017**  
**ECHA Conference Centre (Annankatu 18, Helsinki)**

**13 March starts at 9.00**  
**17 March ends at 13.00**

**Item 1 – Welcome and Apologies**

**Item 2 – Adoption of the Agenda**

***SEAC/A/34/2017***  
***For adoption***

**Item 3 – Declarations of conflicts of interest to the Agenda**

**Item 4 – Report from other ECHA bodies and activities**

- a) Report on SEAC-33 action points, written procedures and update on other ECHA bodies

***SEAC/34/2017/01***  
***For information***

**Item 5 – Restrictions**

**5.1 Restriction Annex XV dossiers**

- a) Conformity check
- 1) Diisocyanates – outcome of the conformity check and presentation of the key issues
  - 2) Lead and lead compounds in PVC – outcome of the conformity check and presentation of the key issues

***For agreement***

b) Opinion development

- 1) TDFAs – third draft opinion
- 2) 4 phthalates – third draft opinion

***For discussion and agreement***

**5.2 Appointment of (co-)rapporteurs for restriction dossiers**

***SEAC/34/2017/02***

***(restricted document)***

***For agreement***

**Item 6 – Authorisation**

**6.1 General authorisation issues**

a) Updated working procedure for authorisation process

***SEAC/34/2017/03***

***SEAC/34/2017/04***

***For information***

b) Update on incoming/future applications

c) Report on AfA Task Force and related activities

d) Feedback from seminar 'Man via the Environment'

***For information***

**6.2 Authorisation applications**

a) Discussion on key issues

1. SD\_Colle (1 use)
2. CT\_Hansgrohe (2 uses)
3. SD\_Hapoc (1 use)

***For discussion***

b) Agreement on draft opinions

1. CT\_Reachlaw (4 uses)
2. CT\_Clariant (1 use)
3. CT\_Cryospace (1 use)
4. SD\_Borealis (1 use)
5. SD\_Ormezzano (2 uses)
6. AD\_BAE (2 uses)
7. EDC\_Biotech (1 use)
8. EDC\_ORGAPHARM (2 uses)
9. EDC\_Akzo (1 use)
10. EDC\_Bayer (1 use)
11. EDC\_Olon (2 uses)
12. Diglyme\_Isochem (1 use)

***For discussion and agreement***

c) Discussion on draft opinions

1. MOCA\_Reachlaw (1 use)
2. CT\_Haas (1 use)
3. SD\_Haas (1 use)
4. PD\_Haas (1 use)
5. SC\_Aviall (2 uses)
6. CT\_Hapoc (4 uses)
7. CT\_Hapoc\_2 (1 use)
8. CT\_Hapoc\_3 (1 use)

***For discussion***

d) Adoption of final opinions

1. AsA\_Circuit (1 use)
2. CT\_Circuit (1 use)
3. CT\_Gerhardi (1 use)

***For discussions and adoption***

**6.3 Appointment of (co-)rapporteurs for authorisation applications  
(closed session)**

***SEAC/34/2017/05  
(restricted room document)  
For agreement***

**Item 7 – AOB**

- a) Update of the work plan
- b) Inventory of valuation studies completed recently in Nordic collaboration
- c) ECHA work on substitution

***For information***

**Item 8 – Action points and main conclusions of SEAC-34**

Table with Conclusions and Action points from SEAC-34

***For adoption***

